MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab plus daratumumab plus lenalidomide (EDR) versus daratumumab plus lenalidomide plus dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM)

被引：0
|
作者：
Kull, M. [1 ]
Grosicki, S. [2 ]
Yeh, S. -P. [3 ]
Huang, J. S. Y. [4 ]
Byun, J. M. [5 ]
DiRienzo, C. [6 ]
Viqueira, A. [7 ]
机构：
[1] Univ Hosp Ulm, Dept Hematol, Ulm, Germany
[2] Med Univ Silesia, Dept Hematol & Canc Prevent, Katowice, Poland
[3] China Med Univ Hosp, Taichung, Taiwan
[4] Taiwan Univ Hosp, Taipei, Taiwan
[5] Seoul Natl Univ Hosp, Seoul, South Korea
[6] Pfizer Inc, New York, NY USA
[7] Pfizer SLU, Madrid, Spain
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1105
引用
收藏
页码：314 / 314
页数：1
相关论文
共 50 条
  • [41] Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Vs Ld in Patients with Newly Diagnosed Multiple Myeloma: Phase 2, Randomized, Open-Label Study in Japan
    Takezako, Naoki
    Ohta, Kensuke
    Handa, Hiroshi
    Hori, Mitsuo
    Kinoshita, Gen
    Shelat, Suresh
    Miyoshi, Masafumi
    Kubo, Kohmei
    BLOOD, 2017, 130
  • [42] Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
    Rajkumar, S. Vincent
    Jacobus, Susanna
    Callander, Natalie S.
    Fonseca, Rafael
    Vesole, David H.
    Williams, Michael E.
    Abonour, Rafat
    Siegel, David S.
    Katz, Michael
    Greipp, Philip R.
    LANCET ONCOLOGY, 2010, 11 (01): : 29 - 37
  • [43] A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study
    Nooka, Ajay K.
    Kaufman, Jonathan L.
    Rodriguez, Cesar
    Jakubowiak, Andrzej
    Efebera, Yvonne
    Reeves, Brandi
    Wildes, Tanya
    Holstein, Sarah A.
    Anderson Jr, Larry D.
    Badros, Ashraf
    Shune, Leyla
    Chari, Ajai
    Pei, Huiling
    Cortoos, Annelore
    Patel, Sharmila
    Lin, Thomas S.
    Richardson, Paul G.
    Voorhees, Peter
    FUTURE ONCOLOGY, 2022, 18 (40) : 4443 - 4456
  • [44] Safety and clinical activity of belantamab mafodotin plus lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: The phase 1/2, prospective, open-label, BelaRd study
    Terpos, Evangelos
    Gavriatopoulou, Maria
    Ntanasis-Stathopoulos, Ioannis
    Malandrakis, Panagiotis
    Fotiou, Despina
    Migkou, Magdalini
    Theodorakakou, Foteini
    Spiliopoulou, Vasiliki
    Syrigou, Rodanthi
    Papaiakovou, Evangelos Eleutherakis
    Gkolfinopoulos, Stavros
    Manousou, Kyriaki
    Kastritis, Efstathios
    Dimopoulos, Meletios A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Melphalan and Prednisone: A Case-Control Study in Newly Diagnosed Elderly Myeloma Patients.
    Gay, Francesca
    Rajkumar, S. Vincent
    Falco, Patrizia
    Kumar, Shaji
    Dispenzieri, Angela
    Gertz, Morie
    Di Raimondo, Francesco
    Lacy, Martha Q.
    Crippa, Claudia
    Buadi, Francis
    Falcone, Antonietta
    Hayman, Suzanne R.
    Giuliani, Nicola
    Short, Kristen E. Detweiler
    Musto, Pellegrino
    Roy, Vivek
    Corradini, Paolo
    Fonseca, Rafael
    Petrucci, Maria Teresa
    Greipp, Philip R.
    Boccadoro, Mario
    Stewart, A. Keith
    Palumbo, Antonio
    BLOOD, 2009, 114 (22) : 1123 - 1123
  • [46] Cost-Effectiveness of Daratumumab Plus Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: An Analysis of the Pollux Trial
    Maiese, Eric M.
    Graham, Christopher N.
    Hawe, Emma
    Le Moine, Jean-Gabriel
    Abraham, Ivo
    Senbetta, Mekre
    BLOOD, 2017, 130
  • [47] Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
    Facon, Thierry
    Kumar, Shaji K.
    Plesner, Torben
    Orlowski, Robert Z.
    Moreau, Philippe
    Bahlis, Nizar
    Basu, Supratik
    Nahi, Hareth
    Hulin, Cyrille
    Quach, Hang
    Goldschmidt, Hartmut
    O'Dwyer, Michael
    Perrot, Aurore
    Venner, Christopher P.
    Weisel, Katja
    Mace, Joseph R.
    Raje, Noopur
    Tiab, Mourad
    Macro, Margaret
    Frenzel, Laurent
    Leleu, Xavier
    Ahmadi, Tahamtan
    Wang, Jianping
    Van Rampelbergh, Rian
    Uhlar, Clarissa M.
    Tromp, Brenda
    Delioukina, Maria
    Vermeulen, Jessica
    Usmani, Saad Z.
    LANCET ONCOLOGY, 2021, 22 (11): : 1582 - 1596
  • [48] Daratumumab (DARA) plus Lenalidomide/Bortezomib/Dexamethasone (RVd) in African American/Black Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of GRIFFIN
    Nooka, Ajay K.
    Kaufman, Jonathan L.
    Rodriguez, Cesar
    Jakubowiak, Andrzej
    Shune, Leyla
    Badros, Ashraf
    Chari, Ajai
    Richardson, Paul G.
    Pei, Huiling
    Ukropec, Jon
    Vermeulen, Jessica
    Hoehn, Daniela
    Lin, Thomas S.
    Voorhees, Peter M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S308 - S309
  • [49] Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study
    Hiroyuki Takamatsu
    Shinsuke Iida
    Hirohiko Shibayama 
    Kazuhiro Shibayama
    Hiroshi Yamazaki
    Kenshi Suzuki
    International Journal of Hematology, 2020, 111 : 692 - 701
  • [50] Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study
    Takamatsu, Hiroyuki
    Iida, Shinsuke
    Shibayama, Hirohiko
    Shibayama, Kazuhiro
    Yamazaki, Hiroshi
    Suzuki, Kenshi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (05) : 692 - 701
12345